Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 4/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40665 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18871260 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29754 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810706 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2903546 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL17210997 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5091966 | 0.90 | TK2 (0.47) | PYGMCDK1TK2TYMP | |
| SCHEMBL20830476 | 0.90 | PYGM (0.45) | PYGMCDK1TK2P2RY2 | |
| SCHEMBL12642176 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP | |
| SCHEMBL22460365 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1869 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| EP-4029522-B1 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| EP-4598935-A2 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-120092014-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4408886-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2024-08-07 | — | — | EP | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| CN-118176209-A | Treatment involving non-immunogenic RNA and PD-1 axis binding antagonists for antigen vaccination | 生物技术公司 | 2024-06-11 | — | — | CN | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | claimed |
| US-20160250321-A1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2016-09-01 | — | — | US | claimed |
| US-9226959-B2 | Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant | CUREVAC AG (DE) | 2016-01-05 | — | — | US | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| CN-103328655-A | Signal amplification | SPEEDX PTY LTD | 2013-09-25 | — | — | CN | claimed |
| EP-2201118-B1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2012-04-18 | — | — | EP | claimed |
| CN-101341260-A | Multi-component nucleases and methods of use thereof | JOHNSON & JOHNSON RES PTY LTD (AU) | 2009-01-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885CDK1 4015/4885SLC28A1 231/4885 |
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | RNGTT, RNMT, NSUN3 | PYGM 689/4885CDK1 4415/4885SLC28A1 684/4885 |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | PYGM 2384/4885CDK1 3069/4885SLC28A1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.